ACTU Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -11.76%, SMA50 -8.75%, SMA200 -19.41%). The stock’s 14-day RSI is 38.12 (weak momentum), while the ATR of 0.49 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.96% below its high and over 11.88% above its low. Average 10-day trading volume of 48.97 thousand shares is below the 3-month average of 74.09 thousand, indicating normal recent market interest.

Actuate Therapeutics Inc has 23.24 million shares outstanding. The public float is 8.37 million shares, elevated short interest at 4.49% of float. This equals 437.44 thousand shares. The short ratio is 5.23 days. Institutional investors hold 63.3% of the float. Insiders own 15.92%. Bios Equity COF, LP holds 71.43 thousand shares, Kreis Leslie W. has 71.43 thousand shares and Fletcher Aaron G.L. has 71.43 thousand shares.

Actuate Therapeutics Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.44. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 24.14% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $20.00. The high target offers 226.8% upside. The low target suggests 226.8% downside. The mean target is $20.00. This offers 226.8% upside. Actuate Therapeutics Inc earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -7.41%. The prior quarter beat by 57.89%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in November 13, 2024.

Actuate Therapeutics Inc (NASDAQ:ACTU) closed at $6.12 USD, gaining $0.10 (1.66%) from the previous close of $6.02. The stock is currently mid-range between its 52-week high and low $5.47 and $11.99. With a market capitalization of about $142.25 million, Actuate Therapeutics Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.33). Key stats such as the average daily volume over the past year has been around 69.90 thousand shares, in line with its 52-week average. Headquartered in Fort Worth, TX, Actuate Therapeutics Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel Schmitt, the company employs approximately 10 people and listed since August 13, 2024. Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers.

Actuate Therapeutics Inc trades at a P/E ratio of -5.18, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 11.42 reflecting a rich premium to book value. The P/FCF stands at -6.71, also above market averages. Compared to sector medians, Actuate Therapeutics Inc P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Actuate Therapeutics Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.38%, with price expected at $5.24 by January 13, 2026, within a range of $4.91 to $5.58 3-Month Outlook: Projected fall of -90.69%, reaching $0.57 by March 30, 2026, with a range of $0.42 to $0.75. 1-Year Outlook: Projected gain of 33.01%, with price at $8.14 by December 30, 2026, within a range of $8.04 to $8.26.

currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Actuate Therapeutics Inc trading at a premium to the broader market with a P/E of -5.18. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.00, suggesting 226.8% upside. Our AI forecast model points to short-term weakness (-14.38% over two weeks), a medium-term fall (-90.69% over three months), and a longer-term gain (33.01% over one year), with expected trading ranges indicating moderate volatility.